This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysExplore ContentEventsMaterialsVideosContact

Menu

Close

HomeEfficacy & SafetyEfficacy & SafetyEfficacyTolerabilityDosingDosingDosing and AdministrationPharmacologySavings & SupportSavings & SupportProtect Your PrescriptionsPRISTIQ Savings Card*Patient Resources
Prescribing Information, including BOXED WARNINGMedication Guide Indication Patient SiteMedical Information
TolerabilityPRISTIQ 50 mg tolerability is comparable to placebo across several indicators7-9Summary
Scroll left to view table
Low discontinuation rates in a pooled analysis of 8-week studies
PRISTIQ 50 mg 4.1% vs 3.8% Placebo
Scroll left to view table
Low incidence of sexual dysfunction across 8-week studies
PRISTIQ 50 mg 1% vs 0% Placebo
Scroll left to view table
No clinical difference in weight gain in 8-week studies
PRISTIQ 50 mg -0.97 lb vs -0.07 lb Placebo
There are serious risks associated with PRISTIQ. For more details, please see the BOXED WARNING and Important Safety Information. ​​​​​​​

12-week study description

Data from a double-blind, randomized, placebo-controlled, fixed-dose, 12-week study of PRISTIQ 50 mg qd (n=282) vs placebo (n=141) in adults aged 18 or older with MDD. The primary end point was the change in HAM-D17 total score vs placebo from baseline at week 12. Weight gain was measured at prespecified time points during the course of these studies. Statistical significance was calculated vs placebo (P>0.05) based on change from baseline to end point; observed cases analysis.9

Discontinuation RatePRISTIQ 50 mg showed low discontinuation rates in a pooled analysis of 8-week studies
Scroll left to view table
 
Low discontinuation rates in a pooled analysis of 8-week studies
PRISTIQ 50 mg 4.1% vs 3.8% Placebo
Scroll left to view table
Most commonly observed adverse reactions
  PRISTIQ 50 mg (n=317) Placebo (n=636)
Nausea 22% 10%
Dizziness 13%  5%
Hyperhidrosis 10% 4%
Constipation 9% 4%
Decreased appetite 5% 2%

Pooled analysis of five 8-week studies. Of the five studies, two examined 50 mg and 100 mg; one examined 100 mg, 200 mg, and 400 mg; and two examined 200 mg and 400 mg.7 Adverse reactions shown are for patients taking PRISTIQ 50 mg vs placebo in 8-week studies (incidence ≥5% and ≥2x the rate of placebo).

8-week study description ​​​​​​​

Pooled 50 mg data (n=317) vs placebo (n=636) from five double-blind, randomized, placebo-controlled, fixed-dose, 8-week studies of 50 mg, 100 mg, 200 mg, and 400 mg qd of PRISTIQ in adults aged 18 or older with MDD (N=2001).7 The primary end point was the change in HAM-D17 total score vs placebo from baseline at week 8.1

Sexual FunctionPRISTIQ 50 mg showed low incidence of sexual dysfunction across 8-week studies
Scroll left to view table
Low incidence of sexual dysfunction across 8-week studies
PRISTIQ 50 mg 1% vs 0% Placebo
Scroll left to view table
Women PRISTIQ 50 mg (n=209) Placebo (n=397)
Anorgasmia 1% 0%
Scroll left to view table
​​​​Men ​​​​PRISTIQ 50 mg (n=108) Placebo (n=239)
Anorgasmia 0% 0%
Libido decreased 4% 1%
Orgasm abnormal 0% 0%
Ejaculation delayed 1% <1%
Erectile dysfunction 3% 1%
Ejaculation disorder 0% 0%
Ejaculation failure 1% 0%
Sexual dysfunction 1% 0%

Pooled analysis of five 8-week studies. Of the five studies, two examined 50 mg and 100 mg; one examined 100 mg, 200 mg, and 400 mg; and two examined 200 mg and 400 mg.8 Incidence of sexual function adverse reactions increased with higher doses.

8-week study description ​​​​​​​

Pooled 50-mg data (n=317) vs placebo (n=636) from five double-blind, randomized, placebo-controlled, fixed-dose, 8-week studies of 50 mg, 100 mg, 200 mg, and 400 mg qd of PRISTIQ in adults aged 18 or older with MDD (N=2001).7 The primary end point was the change in HAM-D17 total score vs placebo from baseline at week 8.1 Sexual function adverse reactions were recorded throughout the study for patients on placebo and PRISTIQ 50 mg.7​

12-week study description

Data from a double-blind, randomized, placebo-controlled, fixed-dose, 12-week study of PRISTIQ 50 mg qd (n=281) vs placebo (n=141) in adults aged 18 or older with MDD. The primary end point was the change in HAM-D17 total score vs placebo from baseline at week 12. The key secondary end point was SDS total score at week 12. Recording of sexual function was completed using the ASEX questionnaire at prespecified time points of baseline, 4, 8, and 12 weeks for patients on placebo and PRISTIQ 50 mg. Although the ASEX analysis was part of the a priori statistical plan, the study was not specifically powered to evaluate changes in sexual function.8,10 Observed cases analysis.

Weight

In a pooled analysis of 8-week studies,

PRISTIQ 50 mg—Weight change vs placebo
Scroll left to view table
No clinical difference in weight gain in 8-week studies
PRISTIQ 50 mg -0.97 lb vs -0.07 lb Placebo
Rates of clinically significant weight change* vs placebo
  • The rates of clinically significant weight gain reported in patients with PRISTIQ 50 mg and placebo were 1.0% and 0.8%, respectively5
  • Additionally, the rates of clinically significant weight loss reported in patients with PRISTIQ 50 mg and placebo were 1.6% and 0.8%, respectively5
Pooled analysis of five 8-week studies. Of the five studies, two examined 50 mg and 100 mg; one examined 100 mg, 200 mg, and 400 mg; and two examined 200 mg and 400 mg.8*Clinically significant weight gain or loss was defined as an increase or decrease of >7% from baseline. Weight change was measured at prespecified time points during the course of these studies.58-week study description ​​​​​​​Pooled 50 mg data (n=317) vs placebo data from five double-blind, randomized, placebo-controlled, fixed-dose, 8-week studies of 50 mg, 100 mg, 200 mg, and 400 mg qd of PRISTIQ in adults aged 18 or older with MDD (N=2001). The primary end point was the change in HAM-D17 total score vs placebo from baseline at week 8. Weight gain was measured at prespecified time points during the course of these studies. Statistical significance was calculated vs placebo (P<0.05) based on change from baseline to end point; observed cases analysis.5,7 Clinically significant weight change reflects analysis from two pooled studies of PRISTIQ 50 mg (n=307) vs placebo (n=309).5,712-week study descriptionData from a double-blind, randomized, placebo-controlled, fixed-dose, 12-week study of PRISTIQ 50 mg qd (n=282) vs placebo (n=141) in adults aged 18 or older with MDD. The primary end point was the change in HAM-D17 total score vs placebo from baseline at week 12. Weight gain was measured at prespecified time points during the course of these studies. Statistical significance was calculated vs placebo (P>0.05) based on change from baseline to end point; observed cases analysis.9In a separate 12-week study9
  • The mean weight changes* from baseline in patients with PRISTIQ 50 mg and placebo were -0.18 lb and 0.09 lb, respectively
  • The rates of clinically significant weight gain† reported in patients with PRISTIQ 50 mg and placebo were 1.4% and 2.1%, respectively
  • Additionally, the rates of clinically significant weight loss† reported in patients with PRISTIQ 50 mg and placebo were 1.4% and 1.4%, respectively
Weight change was measured at prespecified time points during the course of these studies; observed cases analysis.9Clinically significant weight gain or loss was defined as an increase or decrease of ≥7% from baseline.9Most Common Adverse Reactions
Scroll left to view table
Most commonly observed adverse reactions
  PRISTIQ 50 mg (n=317) Placebo (n=636)
Nausea 22% 10%
Dizziness 13% 5%
Hyperhidrosis 10% 4%
Constipation 9% 4%
Decreased appetite 5% 2%

Adverse reactions shown are for patients taking PRISTIQ 50 mg vs placebo in 8-week studies (incidence ≥5% and ≥2x the rate of placebo).

PRISTIQ Savings Card Full Terms and Conditions

By participating in the PRISTIQ Savings Offer Program, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:

  • Patients are not eligible to use this Savings Offer if they are enrolled in a state or federally funded insurance program, including but not limited to Medicaid, Medicare, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”)
  • Patient must have private insurance. Offer is not valid for cash-paying patients. The value of this Savings Offer is limited to $90 per use or the amount of your co-pay, whichever is less
  • Eligible patients may pay a minimum of $4 per monthly prescription fill. By using this Savings Offer, eligible patients may receive a savings of up to $90 per fill off their co-pay or out-of-pocket costs. This Savings Offer is available for a maximum savings of $1,080 per year ($90 per month x 12 months). This Savings Offer may limit your prescription cost to $4, subject to a $90 maximum monthly benefit. Thus, if your co-pay or out-of-pocket cost is more than $94, you will save $90 off of your co-pay or total out-of-pocket costs. [Example: If your co-pay or out-of-pocket costs are $100, you will pay $10 ($100 − $90 = $10).] If your co-pay or out-of-pocket costs are no more than $94, you pay $4. For a mail-order 3-month prescription, your total maximum savings may be $270 ($90 x 3)
  • This Savings Offer is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plans or other health or pharmacy benefit programs
  • You must deduct the savings received under this program from any reimbursement request submitted to your insurance plan, either directly by you or on your behalf
  • You are responsible for reporting use of this Savings Offer to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using this Savings Offer, as may be required. You should not use this Savings Offer if your insurer or health plan prohibits use of manufacturer Savings Offers
  • You must be 18 years of age or older to redeem this Savings Offer
  • This Savings Offer is not valid for Massachusetts or California residents whose prescriptions are covered, in whole or in part, by third-party insurance
  • This Savings Offer is not valid where prohibited by law
  • This Savings Offer cannot be combined with any other savings, free trial, or similar offer for the specified prescription
  • This Savings Offer will be accepted only at participating pharmacies
  • This Savings Offer is not health insurance
  • This Savings Offer is good only in the U.S. and Puerto Rico
  • This Savings Offer is limited to 1 per person during this offering period and is not transferable
  • This Savings Offer may not be redeemed more than once per 30 days per patient
  • No other purchase is necessary
  • Data related to your redemption of this Savings Offer may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other Savings Offer redemptions and will not identify you
  • Pfizer reserves the right to rescind, revoke, or amend the program without notice
  • No membership fees. This Savings Offer and Program expire on 12/31/2025
  • For help with the PRISTIQ Savings Offer, call 1-800-725-4125 or write: PRISTIQ Savings Offer, 2250 Perimeter Park Drive, Suite 300, Morrisville, NC 27560
If your pharmacy does not participate, you may be able to submit a request for a rebate in connection with this Savings Offer. Pay for your PRISTIQ prescription and mail copy of original pharmacy receipt (cash register receipt NOT valid) with product name, date, and amount circled to:PRISTIQ Savings Offer, 2250 Perimeter Park Drive, Suite 300, Morrisville, NC 27560Be sure to include a copy of the front of your PRISTIQ savings card, your name, and mailing address. Please expect up to 4 to 6 weeks for reimbursement.
References:Thase ME, Kornstein SG, Germain JM, Jiang Q, Guico-Pabia C, Ninan PT. An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. CNS Spectr. 2009;14(3):144-154.Rosenthal JZ, Boyer P, Vialet C, Hwang E, Tourian KA. Efficacy and safety of desvenlafaxine 50 mg/d for prevention of relapse in major depressive disorder: a randomized controlled trial. J Clin Psychiatry. 2013;74(2):158-166.Soares CN, Kornstein SG, Thase ME, Jiang Q, Guico-Pabia CJ. Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials. J Clin Psychiatry. 2009;70(10):1365-1371.Leon AC, Olfson M, Portera L, Farber L, Sheehan DV. Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int J Psychiatry Med. 1997;27(2):93-105.Data on file. Pfizer Inc., New York, NY.Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.Clayton AH, Kornstein SG, Rosas G, Guico-Pabia C, Tourian KA. An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. CNS Spectr. 2009;14(4):183-195.Clayton A, Reddy S, Focht K, Musgnung J, Fayyad R. An evaluation of sexual functioning in employed outpatients with major depressive disorder treated with desvenlafaxine 50 mg or placebo. J Sex Med. 2013;10(3):768-776.Dunlop BW, Reddy S, Yang L. Symptomatic and functional improvement in employed depressed patients: a double‐blind clinical trial of desvenlafaxine versus placebo. J Clin Psychopharmacol. 2011;31:569-576.McGahuey CA, Gelenberg AJ, Laukes CA, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther. 2000;26(1):25-40.Preskorn SH, Nichols AI, Paul J, Patroneva AL, Helzner EC, Guico-Pabia CJ. Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system. J Psychiatr Pract. 2008;14(6):368-378.Nichols AI, Focht K, Jiang Q, Preskorn SH, Kane CP. Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study. Clin Drug lnvestig. 2011;31(3):155-167.
Efficacy & Safety
PRISTIQ Savings Card*

Eligible patients may pay as little as $4 per fill*

 Savings Cards Loading

*Eligibility required. Individual savings limited to $90 per fill or $1,080 in maximum total savings per calendar year. Only for use with commercial insurance. If you are enrolled in a state or federally funded prescription insurance program, you may not use the savings card. Terms and conditions apply.

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

PP-PRQ-USA-0922
You are now leaving PfizerYou are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 
​​​​​​​
PP-PRQ-USA-0904
INDICATION PRISTIQ extended-release tablets are indicated for the treatment of major depressive disorder in adults.

Please see Full Prescribing Information, including BOXED WARNING and Medication Guide.
Important Safety Information

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older.
​​​​​​​In patients of all ages who are started on antidepressant therapy, monitor closely for worsening and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber.

​​​​​​​PRISTIQ is not approved for use in pediatric patients.​​​​​​​​​​​​​​

Contraindications

PRISTIQ is contraindicated in patients with a known hypersensitivity to PRISTIQ or venlafaxine. Angioedema has been reported in patients treated with PRISTIQ. 

Serotonin syndrome and MAOIs: Do not use MAOIs intended to treat psychiatric disorders with PRISTIQ or within 7 days of stopping treatment with PRISTIQ. Do not use PRISTIQ within 14 days of stopping an MAOI intended to treat psychiatric disorders. In addition, do not start PRISTIQ in a patient who is being treated with an MAOI such as linezolid or intravenous methylene blue.

Warnings and Precautions

All patients treated with antidepressants should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of treatment and when changing the dose. Consider changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse or includes symptoms of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, mania, or suicidality that are severe, abrupt in onset, or were not part of the patient's presenting symptoms. Families and caregivers of patients being treated with antidepressants should be alerted about the need to monitor patients.

The development of a potentially life-threatening serotonin syndrome has been reported with SSRIs and SNRIs, including with PRISTIQ, both when taken alone, but especially when co-administered with other serotonergic agents (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone,tryptophan, buspirone, amphetamines, and St. John's Wort) and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue). If such events occur, immediately discontinue PRISTIQ and any concomitant serotonergic agents, and initiate supportive treatment. If concomitant use of PRISTIQ with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increase.

Patients receiving PRISTIQ should have regular monitoring of blood pressure, since increases in blood pressure were observed in clinical studies. Pre-existing hypertension should be controlled before starting PRISTIQ. Caution should be exercised in treating patients with pre-existing hypertension, cardiovascular or cerebrovascular conditions that might be compromised by increases in blood pressure. Cases of elevated blood pressure requiring immediate treatment have been reported. For patients who experience a sustained increase in blood pressure, either dose reduction or discontinuation should be considered.

SSRIs and SNRIs, including PRISTIQ, may increase the risk of bleeding events. Concomitant use of aspirin, NSAIDs, warfarin, and other anticoagulants may add to this risk.

The pupillary dilation that occurs following use of many antidepressant drugs, including PRISTIQ, may trigger an angle closure attack in a patient with anatomically narrow angles (Angle Closure Glaucoma) who does not have a patent iridectomy. Avoid use of antidepressants, including PRISTIQ, in patients with untreated anatomically narrow angles.

PRISTIQ is not approved for use in bipolar depression. Prior to initiating treatment with an antidepressant, patients should be adequately screened to determine the risk of bipolar disorder.

PRISTIQ should be used cautiously in patients with a history or family history of mania or hypomania or with a history of seizure disorder.

Adverse reactions after discontinuation of serotonergic antidepressants, particularly after abrupt discontinuation, include nausea, sweating, dysphoric mood, irritability, agitation, dizziness, sensory disturbances, tremor, anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. Patients should be monitored for symptoms when discontinuing treatment. A gradual reduction in dose rather than abrupt cessation is recommended.

SSRIs and SNRIs, including PRISTIQ, may cause symptoms of sexual dysfunction. Patients should be monitored for changes. 

Hyponatremia may occur as a result of treatment with SSRIs and SNRIs, including PRISTIQ. Discontinuation of PRISTIQ should be considered in patients with symptomatic hyponatremia.

Interstitial lung disease and eosinophilic pneumonia associated with venlafaxine (the parent drug of PRISTIQ) therapy have been rarely reported.

Third trimester use may result in neonatal discontinuation syndrome.

Adverse Reactions​​​​​

The most commonly observed adverse reactions in patients taking PRISTIQ vs placebo for MDD in short-term fixed-dose premarketing studies (incidence ≥5% and at least twice the rate of placebo in the 50-mg dose group) were nausea (22% vs 10%), dizziness (13% vs 5%), hyperhidrosis (10% vs 4%), constipation (9% vs 4%), and decreased appetite (5% vs 2%).

Indication PRISTIQ extended-release tablets are indicated for the treatment of major depressive disorder in adults.
​​​​​​​
Please see Full Prescribing Information, including BOXED WARNING, and Medication Guide.